GFR-Based Metformin Safety Checker

Current eGFR (mL/min/1.73m²)

Warning / IV Contrast

For eGFR between 30–60, Metformin should be withheld before IV contrast procedures and for 48 hours afterward, resuming only if renal function remains stable.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

All patients with Type 2 Diabetes on Metformin during routine renal monitoring.

Initial screening before prescribing Metformin.

Evaluating medication safety during acute illness or before procedures requiring intravenous contrast.

How it Works

ADA & FDA Guidelines

eGFR (mL/min/1.73m²)	Metformin Recommendation
≥ 60	No renal dose adjustment. Monitor annually.
45 – 59	Safe to continue. Monitor every 3–6 months.
30 – 44	Reduce dose by 50%. Do not initiate new treatment.
< 30	Contraindicated. Discontinue immediately.

Last Comprehensive Review: 2026

Recent Journal Updates

WHO NewsJul 20, 2026

Road deaths fall by 21% globally but stronger action is needed to save lives

Clinical Context

We think this might be relevant to the clinical guidance for GFR-Based Metformin Safety Checker.

British J Clinical PharmacologyJul 20, 2026

Evaluating the pharmacokinetics, efficacy and safety of low‐dose cannabidiol

Clinical Context

We think this might be relevant to the clinical guidance for GFR-Based Metformin Safety Checker.

WHO NewsJul 15, 2026

New WHO guidelines: up to 45% of dementia risk could be prevented or delayed

Clinical Context

We think this might be relevant to the clinical guidance for GFR-Based Metformin Safety Checker.

GFR-Based Metformin Safety Checker

When to Use

When to Use

How it Works

ADA & FDA Guidelines

Clinical Pearls

IV Contrast Protocol

Lactic Acidosis Risk

The Evidence

Primary Source

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024

Metformin-containing drugs: revised recommendations for use in patients with reduced kidney function

Recent Journal Updates

GFR-Based Metformin Safety Checker

When to Use

When to Use

How it Works

ADA & FDA Guidelines

Clinical Pearls

IV Contrast Protocol

Lactic Acidosis Risk

The Evidence

Primary Source

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024

Metformin-containing drugs: revised recommendations for use in patients with reduced kidney function

Recent Journal Updates